发明授权
US08664368B2 Fully human monoclonal antibody to VEGF, preparation method and use thereof
有权
VEGF的完全人单克隆抗体，其制备方法和用途
- 专利标题： Fully human monoclonal antibody to VEGF, preparation method and use thereof
- 专利标题（中）： VEGF的完全人单克隆抗体，其制备方法和用途
-
申请号： US13579218申请日： 2010-04-16
-
公开(公告)号： US08664368B2公开(公告)日： 2014-03-04
- 发明人: Shuhui Wang , Chuan Li , Ying Kan , Xin Tong
- 申请人： Shuhui Wang , Chuan Li , Ying Kan , Xin Tong
- 申请人地址： CN Shanghai
- 专利权人： Shanghai Biomabs Pharmaceuticals Co., Ltd.
- 当前专利权人： Shanghai Biomabs Pharmaceuticals Co., Ltd.
- 当前专利权人地址： CN Shanghai
- 代理机构： Cesari and McKenna, LLP
- 优先权： CN201010125263 20100225
- 国际申请： PCT/CN2010/000513 WO 20100416
- 国际公布： WO2011/103702 WO 20110901
- 主分类号： C07K16/22
- IPC分类号： C07K16/22 ; C07K16/18 ; C07K14/475 ; A61K39/395
摘要：
The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.
公开/授权文献
信息查询
